Therefore, the stimulation of the immune response by the intestinal microbiota via TLR/MyD88 and the activation of IL–1 family of cytokines, which also signal through MyD88 adaptor protein, seem to be relevant in the context of the mucositis associated with this anticancer treatment. The gene discussed is IL1B; the disease is mucositis.